Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
Journal of Cellular Physiology - United States
doi 10.1002/jcp.25432
Full Text
Open PDFAbstract
Available in full text
Date
June 2, 2016
Authors
Publisher
Wiley